Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.